vTv Therapeutics is mentioned in the article as Cantex Pharmaceuticals' partner. Cantex has licensed exclusive rights to Azeliragon from Georgetown University for potential cancer-related cognitive decline treatment. If the treatment proves successful, it may have a positive impact on vTv Therapeutics' stock price in the short term.